Use of NK-1 receptor antagonists against benign prostatic hyperplasia

Details for Australian Patent Application No. 2002250876 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Sleight, Andrew John; Vankan, Pierre; Buser, Susanne; Ford, Anthony P., D. W.; Hoffmann, Torsten; Lenz, Barbara

Agent Spruson & Ferguson

Pub. Number AU-B-2002250876

PCT Pub. Number WO2002/085458

Priority 01109853.0 23.04.01 EP

Filing date 2 February 2002

Wipo publication date 5 November 2002

Acceptance publication date 3 March 2005

International Classifications

A61P 013/08 Drugs for disorders of the urinary system

A61K 031/44 - Non-condensed pyridines

A61K 031/455 - Nicotinic acid, i.e. niacin

Event Publications

17 April 2003 Application Open to Public Inspection

  Published as AU-B-2002250876

3 March 2005 Application Accepted

  Published as AU-B-2002250876

30 June 2005 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002250877-IMPROVED DISPOSABLE PREFILLED SYRINGE

2002250875-USE OF GALANTAMINE FOR ACCELERATING TRANSPORT OF INTRALUMINAL CONTENT